Late Reports on Adverse Events Land Ariad Pharmaceuticals 483

Late Reports on Adverse Events Land Ariad Pharmaceuticals 483

March 13, 2015

Ariad Pharmaceuticals failed to submit a slew of adverse event reports within the 15-day deadline and follow the risk evaluation and mitigation strategy for its blockbuster leukemia drug Iclusig, prompting a 483. Read More